AI assistant
Median Technologies Share Issue/Capital Change 2025
1514_dva_2025-07-07_34ff5b33-90fd-4837-b3b8-51bfe9f3ce19.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
M
median
Press release – For immediate release
July 7, 2025 – 5:45 pm CEST
Disclosure of total number of voting rights and number of shares in the capital as of June 30, 2025
Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
Sophia Antipolis, France
| Total number of shares | 19,493,281 |
|---|---|
| Number of real voting rights* | |
| (excluding treasury shares**) | 19,409,273 |
| Theoretical number of voting rights* | |
| (including treasury shares**) | 19,470,081 |
() Class E preference shares are non-voting
(*) pursuant to article 223-11 of the AMF’s General Regulations
About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com.
Contacts
Median Technologies
Emmanuelle Leygues
VP, Corporate Marketing & Financial Communications
+33 6 10 93 58 88
Investors - ACTIFIN
Ghislaine Gasparetto
+33 6 21 10 49 24
Press – Ulysse Communication
Bruno Arabian
+33 6 87 88 47 26
Nicolas Entz
+33 6 33 67 31 54